Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch Maintenance Study of TAS-102 plus bevacizumab after oxaliplatin-based induction in metastatic colorectal cancer
jRCT1051180117Phase 2Active, not recruiting
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC). Primary endpoint: Progression-free survival. Started Jan 2018; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1051180117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051180117.